Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. - Test2 - elhamkhani - TriplyDB

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

http://www.wikidata.org/entity/Q37108889

about

Potential use of NOACs in developing countries: pros and cons.The WATCHMAN device for stroke prophylaxis in atrial fibrillation: an evolving niche.

P2860

Q38210994-1DF81AF6-6818-48F5-98D8-69F93962C060 Q38307591-91B8AE93-BAFC-4139-A073-CFB940180DA0

P2860

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

http://www.wikidata.org/entity/Q37108889

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Potential impact of new oral a ...... elated stroke in primary care.

@en

Potential impact of new oral a ...... elated stroke in primary care.

@nl

type

label

Potential impact of new oral a ...... elated stroke in primary care.

@en

Potential impact of new oral a ...... elated stroke in primary care.

@nl

prefLabel

Potential impact of new oral a ...... elated stroke in primary care.

@en

Potential impact of new oral a ...... elated stroke in primary care.

@nl

P1433

Q37108889-7A37156A-3109-46EB-9B53-ED31B58A6B7C

P1476

Q37108889-DE749DC1-2C1D-41F0-B00D-AE71D2F754C7

P2093

Q37108889-3DB87423-243E-4C96-A326-50D262EC293A

Q37108889-A0C8A6BB-CEAA-4532-960C-6EF3F68A9183

P275

Q37108889-80103BA8-55A3-45C1-AF2C-66B6CF516953

P2860

Q37108889-0A41A85D-6444-4E04-9322-9AE610F3BB4A

Q37108889-0A8B7B5B-D505-4C16-863A-4D9A1315E4E6

Q37108889-0D665291-9ADE-4EFE-B3B6-EB8E802458CB

Q37108889-164E2BEE-7A55-4A7F-B96E-CF8735A70574

Q37108889-1E0FF82F-8A5E-4111-AF9F-9C1A2592425A

Q37108889-256458B4-2A74-4F7E-9EB4-6654B413DDA6

Q37108889-28B56F94-D6FD-4689-A468-0A247AE07BDE

Q37108889-40015AC4-23FB-43E1-BEB0-BD8002355DF4

Q37108889-454F3368-762F-424E-B9EA-EFF56DF22CF8

Q37108889-4AFB1117-291F-4751-86D3-D8E8C2D1F2A5

P304

Q37108889-49036582-943E-41C7-8D3A-3A9FB9E99ED6

P31

Q37108889-9BB1D95B-9A19-483D-88A7-D1C8867F2140

Q37108889-B17889F4-6CBC-4C5D-B55B-8BF12C0711CF

P356

Q37108889-EBBAB1CE-CA5D-414C-83AE-95D47D2A406B

P433

Q37108889-680A508C-522B-429F-8487-EE5E89B9C320

P478

Q37108889-A94D3BE7-DD38-4E12-B499-181ADA77885E

P5008

Q37108889-E214DD2F-D4D2-4C8F-BFFC-3DA82A000DCD

P577

Q37108889-55017DEA-F2E7-4BED-96FB-091F4F6C57E9

Q37108889-5B55B509-0060-4609-B48C-4383FDB41114

P5875

Q37108889-2E7BCEBE-CAAE-4D36-84AD-10B6C87F0059

P698

Q37108889-FC9E254E-47DE-4AC9-90AD-5625488AE3F3

P921

Q37108889-3B49902E-5DAB-458B-8ABE-D885BC498146

Q37108889-66D44103-C7BD-457A-8DFD-103C9EBD764C

Q37108889-69C83A80-9723-4329-8008-F4D5DFB69165

Q37108889-DA3C3687-2496-4C32-BE92-347980947B91

P932

Q37108889-22C09C6A-75C2-4835-9ABD-90CFFFD1CB6B

P356

P1433

International Journal of Clinical Practice

P1476

Potential impact of new oral a ...... elated stroke in primary care.

@en

P2093

J Mant

http://www.w3.org/2001/XMLSchema#string

K Harris

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

Incidence of chronic atrial fibrillation in general practice and its treatment pattern

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis

The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

Comorbidity associated with atrial fibrillation: a general practice-based study

P304

647-655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12177

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236456454

http://www.w3.org/2001/XMLSchema#string

P698

23621153

http://www.w3.org/2001/XMLSchema#string

P921

cerebrovascular disease

anticoagulation

atrial fibrillation

P932

3748790

http://www.w3.org/2001/XMLSchema#string